Patent assignee · US · COMPANY

MicroVAX, LLC

26Patents
25Active
26Granted
46Portfolio score

Filing activity: Nov 23, 2004 → Apr 22, 2022 · 2 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8828957B2 Methods for generating immunity to antigen Chemistry; Metallurgy 6 Active
US8299229B2 Mucin antigen vaccine Chemistry; Metallurgy 6 Expired
US9533036B2 Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein Chemistry; Metallurgy 4 Active
US8501707B2 Mucin antigen vaccine Chemistry; Metallurgy 4 Active
US10046041B2 Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus Chemistry; Metallurgy 2 Active
US9353167B2 Methods for generating immunity to antigen Chemistry; Metallurgy 2 Active
US8742087B2 Mucin antigen vaccine Chemistry; Metallurgy 2 Active
US9402920B2 Mucin antigen vaccine Chemistry; Metallurgy 1 Active
US9526774B1 Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus Chemistry; Metallurgy 1 Active
US9642901B1 TAA/CD40L vaccine for malaria Emerging Cross-Sectional Technologies 1 Active
US10383932B2 Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells Chemistry; Metallurgy 1 Active
US9757438B2 Mucin antigen vaccine Chemistry; Metallurgy 1 Active
US12427191B1 SARS-CoV-2 fusion protein vaccine/regimen Chemistry; Metallurgy 0 Active
US11839655B2 Combination cancer therapy Chemistry; Metallurgy 0 Active
US10293040B1 Pharmaceutical compositions and methods of blocking Bacillus anthracis Chemistry; Metallurgy 0 Active
US10835589B2 Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD40L/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells Chemistry; Metallurgy 0 Active
US10130667B1 TAA/ecdCD40L oncolytic virus Chemistry; Metallurgy 0 Active
US9889188B1 Ebola virus composition/vaccine Chemistry; Metallurgy 0 Active
US10183067B1 TAA/CD4OL composition/vaccine for malaria Emerging Cross-Sectional Technologies 0 Active
US10166284B1 Vaccines for herpes simplex virus 1 and 2 Chemistry; Metallurgy 0 Active
US10149899B1 Composition and method against C-difficile Chemistry; Metallurgy 0 Active
US11154603B1 Burkholderia pseudomallei composition Chemistry; Metallurgy 0 Active
US10174100B1 Multivalent DNA composition for Yersinia pestis Chemistry; Metallurgy 0 Active
US11077183B2 CD40 ligand fusion protein vaccine Chemistry; Metallurgy 0 Active
US10426827B1 Dengue hemorrhagic fever virus vaccine Emerging Cross-Sectional Technologies 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.